Lv5
956 积分 2024-12-28 加入
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
3个月前
已完结
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study
3个月前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
3个月前
已完结
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
5个月前
已完结
Immune checkpoint inhibitor therapy
5个月前
已完结
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)
5个月前
已完结
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
5个月前
已完结
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
5个月前
已完结
Case report: Electrocardiographic changes in pembrolizumab-induced fatal myocarditis
5个月前
已完结
Correction to: Routine application of cardiac magnetic resonance imaging in patients with suspected myocarditis from immune checkpoint inhibitor therapy
5个月前
已关闭
皖公网安备34019202002308
